AVN-322

AVN-322 is a 5-hydroxytryptamine subtype 6 receptor antagonist manufactured by Avineuro Pharmaceuticals Inc. that could potentially be used to combat Alzheimer's disease and schizophrenia. AVN-322 also reverses the negative effects of scopolamine and MK-80.

The compound is a sister drug to AVN-101 and AVN-211, two similar compounds under trial for treating Alzheimer's. Phase I trials for the drug were initiated in 2009 by Avineuro, and completed in the spring of 2010. The trials showed that AVN-322 was tolerated in a range of doses without any adverse effects, and Avineuro released plans to commence Phase II trials later the same year. The plan for further trials was discontinued in 2013.